Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease.


Journal

Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 1 7 2019
medline: 18 12 2019
entrez: 1 7 2019
Statut: ppublish

Résumé

Secondary prevention of peripheral arterial disease includes administration of statins regardless of the patient's serum cholesterol level. Our study aimed to identify patient-associated risk factors for statin non-persistence and comparison of the explanatory power of models based on clusters of patient-associated characteristics. Our study cohort (n = 8330) was assembled from the database of the largest health insurance provider in the Slovak Republic. Statin users aged ≥ 65 years in whom peripheral arterial disease was diagnosed during 2012 were included. Patients were followed for 5 years; those with a treatment gap period of at least 6 months without statin prescription were classified as "non-persistent". The risk factors for non-persistence were identified within six models (sociodemographic, cardiovascular events, comorbid conditions, statin-related characteristics, cardiovascular co-medication and full model) using Cox regression. The explanatory power of models was assessed using Harrell's C-index. At the end of the follow-up, 35.7% of patients were found to be non-persistent. The full model had the highest explanatory power (C = 0.632). Female sex, atorvastatin and rosuvastatin as initially administered statins, being a new statin user and an increasing co-payment were associated with an increased risk for non-persistence. Increasing age, history of ischaemic stroke, diabetes mellitus, general practitioner as index prescriber, increasing overall number of medications and co-administration of certain cardiovascular co-medications were associated with a lower likelihood for non-persistence. Patients identified as high risk for non-persistence require special attention aimed at the improvement of their persistence with statin treatment.

Sections du résumé

BACKGROUND AND OBJECTIVES
Secondary prevention of peripheral arterial disease includes administration of statins regardless of the patient's serum cholesterol level. Our study aimed to identify patient-associated risk factors for statin non-persistence and comparison of the explanatory power of models based on clusters of patient-associated characteristics.
METHODS
Our study cohort (n = 8330) was assembled from the database of the largest health insurance provider in the Slovak Republic. Statin users aged ≥ 65 years in whom peripheral arterial disease was diagnosed during 2012 were included. Patients were followed for 5 years; those with a treatment gap period of at least 6 months without statin prescription were classified as "non-persistent". The risk factors for non-persistence were identified within six models (sociodemographic, cardiovascular events, comorbid conditions, statin-related characteristics, cardiovascular co-medication and full model) using Cox regression. The explanatory power of models was assessed using Harrell's C-index.
RESULTS
At the end of the follow-up, 35.7% of patients were found to be non-persistent. The full model had the highest explanatory power (C = 0.632). Female sex, atorvastatin and rosuvastatin as initially administered statins, being a new statin user and an increasing co-payment were associated with an increased risk for non-persistence. Increasing age, history of ischaemic stroke, diabetes mellitus, general practitioner as index prescriber, increasing overall number of medications and co-administration of certain cardiovascular co-medications were associated with a lower likelihood for non-persistence.
CONCLUSIONS
Patients identified as high risk for non-persistence require special attention aimed at the improvement of their persistence with statin treatment.

Identifiants

pubmed: 31256366
doi: 10.1007/s40266-019-00689-2
pii: 10.1007/s40266-019-00689-2
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

863-873

Références

J Am Heart Assoc. 2017 May 3;6(5):
pubmed: 28468784
Arch Med Res. 2007 Jul;38(5):479-88
pubmed: 17560452
J Am Geriatr Soc. 1985 Jan;33(1):13-8
pubmed: 3965550
Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):201-207
pubmed: 27935151
J Diabetes. 2018 Sep;10(9):699-707
pubmed: 29658177
Am J Alzheimers Dis Other Demen. 2018 Dec;33(8):527-534
pubmed: 29991271
J Cereb Blood Flow Metab. 2005 Sep;25(9):1093-110
pubmed: 15815580
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Clin Pharmacol. 2014 Oct;70(10):1275-6
pubmed: 25146693
J Clin Lipidol. 2014 Jan-Feb;8(1):117-25
pubmed: 24528692
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
J Manag Care Pharm. 2014 Jan;20(1):43-50
pubmed: 24372459
J Am Coll Cardiol. 2014 Feb 25;63(7):682-690
pubmed: 24315911
Drugs Aging. 2018 Aug;35(8):679-686
pubmed: 29987758
Drugs Aging. 2019 Apr;36(4):321-340
pubmed: 30613912
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
Arch Intern Med. 2004 Nov 22;164(21):2343-8
pubmed: 15557413
Drugs Aging. 2018 Jul;35(7):657-663
pubmed: 29916140
J Gerontol A Biol Sci Med Sci. 2018 May 9;73(6):798-805
pubmed: 29360935
Eur Heart J. 2011 Nov;32(22):2851-906
pubmed: 21873417
JAMA. 2002 Jul 24-31;288(4):455-61
pubmed: 12132975
Stat Med. 2011 May 10;30(10):1105-17
pubmed: 21484848
Int Angiol. 2015 Oct;34(5):416-27
pubmed: 25410295
N C Med J. 2016 11-12;77(6):406-409
pubmed: 27864490
Br J Clin Pharmacol. 2019 Jan;85(1):227-235
pubmed: 30402916
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Mayo Clin Proc. 2018 May;93(5):666-668
pubmed: 29728206
J Clin Lipidol. 2013 Sep-Oct;7(5):472-83
pubmed: 24079289
Ir J Med Sci. 2015 Jun;184(2):403-10
pubmed: 24859371
Circulation. 2010 Mar 30;121(12):1455-8
pubmed: 20351303
Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10):
pubmed: 29021332
Curr Atheroscler Rep. 2016 Nov;18(11):63
pubmed: 27696318
J Gerontol A Biol Sci Med Sci. 2018 May 9;73(6):813-819
pubmed: 28958039
Circ Res. 2015 Apr 24;116(9):1579-98
pubmed: 25908730
Clin Drug Investig. 2017 Nov;37(11):1047-1054
pubmed: 28791591
Diabetes Res Clin Pract. 2009 Apr;84(1):e9-e11
pubmed: 19167127
Eur Heart J. 2008 Sep;29(17):2083-91
pubmed: 18664465
Ann Pharmacother. 2019 Jan;53(1):43-49
pubmed: 30084646
Ann Intern Med. 2018 Jul 3;169(1):30-35
pubmed: 29946690
J Am Coll Cardiol. 2018 Nov 27;72(21):2675-2677
pubmed: 30466527
Eur J Clin Pharmacol. 2014 Jun;70(6):701-7
pubmed: 24604354
Drugs Aging. 2014 Oct;31(10):721-30
pubmed: 25212952
Am J Cardiol. 2014 Sep 15;114(6):826-31
pubmed: 25103917
Curr Med Res Opin. 2018 Jun;34(6):1013-1019
pubmed: 29292657

Auteurs

Martin Wawruch (M)

Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia. martin.wawruch@gmail.com.

Gejza Wimmer (G)

Institute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia.

Jan Murin (J)

1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Martina Paduchova (M)

Department of Angiology, Health Centre, Trnava, Slovakia.

Tomas Tesar (T)

Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32, Bratislava, Slovakia. tesar@fpharm.uniba.sk.

Lubica Hlinkova (L)

General Health Insurance Company, Bratislava, Slovakia.

Peter Slavkovsky (P)

Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Lubomira Fabryova (L)

Department of Diabetes and Metabolic Disorders, MetabolKLINIK, Bratislava, Slovakia.
Biomedical Research Centre, Slovak Academy of Sciences, Bratislava, Slovakia.

Emma Aarnio (E)

Institute of Biomedicine, University of Turku, Turku, Finland.
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH